Sharp Therapeutics Corp.
SHRX.V
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 5.77% | 419.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.45% | 238.24% | |||
| Operating Income | -8.45% | -238.24% | |||
| Income Before Tax | 117.18% | -2,787.84% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 117.18% | -2,787.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 117.18% | -2,787.84% | |||
| EBIT | -8.45% | -238.24% | |||
| EBITDA | -8.79% | -239.97% | |||
| EPS Basic | 116.31% | -1,730.16% | |||
| Normalized Basic EPS | 116.37% | -549.55% | |||
| EPS Diluted | 116.31% | -1,730.16% | |||
| Normalized Diluted EPS | 116.37% | -549.55% | |||
| Average Basic Shares Outstanding | 5.12% | 58.04% | |||
| Average Diluted Shares Outstanding | 5.12% | 58.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||